| Androgen signaling in prostate cancer C Dai, H Heemers, N Sharifi Cold Spring Harbor perspectives in medicine 7 (9), a030452, 2017 | 438 | 2017 |
| Corticosteroids compromise survival in glioblastoma KL Pitter, I Tamagno, K Alikhanyan, A Hosni-Ahmed, SS Pattwell, ... Brain 139 (5), 1458-1471, 2016 | 360 | 2016 |
| Analytic and clinical validation of a prostate cancer–enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival DC Danila, A Anand, N Schultz, G Heller, M Wan, CC Sung, C Dai, ... European urology 65 (6), 1191-1197, 2014 | 93 | 2014 |
| Targeting the androgen signaling axis in prostate cancer C Dai, SM Dehm, N Sharifi Journal of Clinical Oncology 41 (26), 4267-4278, 2023 | 53 | 2023 |
| Functional silencing of HSD17B2 in prostate cancer promotes disease progression X Gao, C Dai, S Huang, J Tang, G Chen, J Li, Z Zhu, X Zhu, S Zhou, ... Clinical Cancer Research 25 (4), 1291-1301, 2019 | 50 | 2019 |
| Intermediate-term outcomes for men with very low/low and intermediate/high risk prostate cancer managed by active surveillance YA Nyame, N Almassi, SC Haywood, DJ Greene, V Ganesan, C Dai, ... The Journal of Urology 198 (3), 591-599, 2017 | 43 | 2017 |
| Direct metabolic interrogation of dihydrotestosterone biosynthesis from adrenal precursors in primary prostatectomy tissues C Dai, YM Chung, E Kovac, Z Zhu, J Li, C Magi-Galluzzi, AJ Stephenson, ... Clinical Cancer Research 23 (20), 6351-6362, 2017 | 40 | 2017 |
| Impact of 5α-reductase inhibitors on disease reclassification among men on active surveillance for localized prostate cancer with favorable features C Dai, V Ganesan, J Zabell, YA Nyame, N Almassi, DJ Greene, D Hettel, ... The Journal of Urology 199 (2), 445-452, 2018 | 16 | 2018 |
| Revisiting androgen receptor signaling in breast cancer C Dai, LW Ellisen The Oncologist 28 (5), 383-391, 2023 | 14 | 2023 |
| Prognostic significance of a negative confirmatory biopsy on reclassification among men on active surveillance V Ganesan, C Dai, YA Nyame, DJ Greene, N Almassi, D Hettel, J Zabell, ... Urology 107, 184-189, 2017 | 13 | 2017 |
| Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer AA Davis, L Gerratana, K Clifton, AJ Medford, M Velimirovic, WL Hensing, ... EBioMedicine 86, 2022 | 10 | 2022 |
| Cyclin-dependent kinase 4/6 inhibitors beyond progression in metastatic breast cancer: a retrospective real-world biomarker analysis L Gerratana, AA Davis, M Velimirovic, C Reduzzi, K Clifton, L Bucheit, ... JCO Precision Oncology 7, e2200531, 2023 | 8 | 2023 |
| Androgen signaling in prostate cancer. Cold Spring Harb Perspect Med. 2017; 7: a030452 C Dai, H Heemers, N Sharifi | 8 | |
| TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis AJ Medford, L Oshry, B Boyraz, L Kiedrowski, S Menshikova, A Butusova, ... Therapeutic Advances in Medical Oncology 15, 17588359231152844, 2023 | 7 | 2023 |
| Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC … L Gerratana, AA Davis, M Velimirovic, K Clifton, WL Hensing, AN Shah, ... Breast Cancer Research 25 (1), 112, 2023 | 6 | 2023 |
| Androgen Signaling in Prostate Cancer. Cold Spring Harb Perspect Med. 2017; 7 (9) C Dai, H Heemers, N Sharifi Epub 2017/04/09. https://doi. org/10.1101/cshperspect. a030452 PMID: 28389515, 0 | 5 | |
| Older age at diagnosis and initial disease volume predict grade reclassification risk on confirmatory biopsy in patients considered for active surveillance C Dai, V Ganesan, YA Nyame, N Almassi, DJ Greene, D Hettel, ... Urology 130, 106-112, 2019 | 4 | 2019 |
| Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+ … M Velimirovic, L Gerratana, AA Davis, WL Hensing, K Clifton, AN Shah, ... Cancer Research 82 (4_Supplement), P2-07-02-P2-07-02, 2022 | 3 | 2022 |
| Uncovering the differential impact of ESR1 and PIK3CA codon variants on the clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA … L Gerratana, AA Davis, M Velimirovic, P D'Amico, AN Shah, K Clifton, ... Journal of Clinical Oncology 39 (15_suppl), 1033-1033, 2021 | 3 | 2021 |
| Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child JC Keenan, AJ Medford, CS Dai, SA Wander, LM Spring, A Bardia Expert Review of Anticancer Therapy 24 (6), 397-405, 2024 | 2 | 2024 |
